US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MSFT $530.14 ▼-0.16% MU $934.27 ▼-4.98% META $624.52 ▲+1.96% AMZN $243.79 ▼-4.25% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Adagene Inc. - ADS, each representing 1.25 ordinary shares (NQ:ADAG)

2.680 +0.010 (+0.37%)
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adagene Inc. - ADS, each representing 1.25 ordinary shares

< Previous 1 2 3 4 5 Next >
News headline image
Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte’s INCA33890 in Patients with Microsatellite Stable Colorectal Cancer
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer ↗
Adagene (NASDAQ:ADAG) is advancing its masked anti-CTLA-4 antibody, ADG126, also known as muzastotug, in metastatic microsatellite-stable colorectal cancer (MSS CRC) and in a neoadjuvant... 
Via MarketBeat
News headline image
Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts ↗
Adagene (NASDAQ:ADAG) Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company’s antibody pipeline, its approach to masked therapies and upcoming development milestones... 
Via MarketBeat
News headline image
Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene to Participate in Three Upcoming Investor Conferences
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer ↗
Adagene (NASDAQ:ADAG) Chief Strategy Officer Mickael Chane-Du outlined the company’s clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst... 
Via MarketBeat
News headline image
Adagene to Participate in Two Upcoming Investor Conferences
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
From Adagene Inc.
Via GlobeNewswire
News headline image
Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA
From Adagene Inc.
Via GlobeNewswire
Top movers in Wednesday's session ↗
Via Chartmill
News headline image
Adagene to Participate in Two Upcoming Investor Conferences
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Provides Business Update and 2026 Objectives
From Adagene Inc.
Via GlobeNewswire
News headline image
These stocks are gapping in today's session ↗
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
From Adagene Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
From Adagene Inc.
Via GlobeNewswire
News headline image
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
From Adagene Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
From Adagene Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >